Perlegen Sciences and 454 Life Sciences (now owned by Roche) have teamed up to conduct large scale genetic re-sequencing in DNA samples collected from people with specific responses to an undisclosed class of drug. The companies hope to identify a specific genetic variation and create a test to administer to patients taking the drug that will determine what their response will be. "This study holds the promise to improve therapeutic outcomes for a vast number of patients," noted Bryan Walser, MD, CEO of Perlegen. Perlegen was a 2003 Fierce 15 company.
- check out the release on the deal
Related Articles:
Roche snares 454's sequencing tech in buyout. Report
454 makes big advance in sequencing technology. Report
Perlegen strikes collaboration deal with Genentech. Report